Application of α-mangostin and its derivatives in the preparation of feed additives for preventing and treating dolphin streptococcal disease in fish

By combining α-repellin and its derivatives with fish feed, as a natural feed additive, the prevention and treatment problems of fish dolphin streptococci disease are solved, and efficient and safe prevention and treatment effects are achieved, avoiding drug residues and the environment. Pollution has broad application prospects.

CN118000308BActive Publication Date: 2024-11-19HAINAN UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410235867.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2023-12-05
Filing Date
2024-03-01
Publication Date
2024-11-19
Estimated Expiration
2044-03-01

AI Technical Summary

Technical Problem

The prior art has problems of drug resistance, environmental pollution and high cost when preventing and treating fish dolphin streptococcosis, and lacks safe and efficient green drugs.

Method used

Alpha-tretin and its derivatives are used as feed additives to prevent and treat Streptococcus dolphins as natural compounds by combining with fish feed, and to improve the survival rate of fish using its antibacterial and antioxidant properties.

Benefits of technology

The relative survival rate of diseased fish is improved within the effective dose, reaching 32.14% to 67.86%. In addition, α-repellent is safe and non-toxic to fish, easy to metabolize and eliminate, avoid drug residues and environmental pollution, and has industrial preparation potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118000308B_ABST
    Figure CN118000308B_ABST
Patent Text Reader

Abstract

The present invention relates to the application of α-mangostin and its derivatives in the preparation of feed additives for preventing and treating fish dolphin streptococcal disease, and belongs to the technical field of drugs for preventing and treating fish dolphin streptococcal disease. The technical problem solved by the present invention is to provide an application of α-mangostin and its derivatives in the preparation of feed additives for preventing and treating fish dolphin streptococcal disease. The present invention is the first to apply the natural compound α-mangostin as a feed additive to prevent and treat fish dolphin streptococcal disease, especially to prevent and treat dolphin streptococcal disease in tilapia, which can improve the relative survival rate of sick tilapia. α-mangostin has good biocompatibility, low side effects, and an industrial preparation process. It has great potential for development into a new type of feed additive for preventing and treating fish dolphin streptococcus, and has broad application prospects. It is easy to be metabolized and eliminated in the host body, and is easily degraded and eliminated in the environment, which is conducive to promoting the sustainable and healthy development of aquaculture.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to application of alpha-mangostin and derivatives thereof in preparing feed additives for preventing and treating fish streptococcus dolphinus disease, belonging to the technical field of drugs for preventing and treating fish streptococcus dolphinus disease. Background Art

[0002] Streptococcus iniae is a facultative anaerobic Gram-positive bacterium, generally spherical or oval, with a diameter of about 0.2-0.8 μm, with capsule, no spore formation, and no motility. The main symptoms of Streptococcus iniae in fish are protruding eyes, blackened body surface, rolling, congestion and swelling of internal organs, and effusion, which can cause sudden death of a large number of fish. Streptococcus iniae has strong resistance to stress and immune evasion ability, can survive and proliferate in host macrophages, and then spread to various tissues of the host through macrophages like a Trojan horse, aggravating the infection and causing a large number of deaths in the host, which increases the difficulty of its prevention and treatment. For the current prevention and treatment of Streptococcus iniae in fish, the main antibiotics and sulfonamides are enrofloxacin, cefotaxime, cephradine, cefazolin, kanamycin, etc., which have shortcomings such as pathogen resistance, environmental pollution, and drug residues. There is an urgent need for green and safe drugs with controllable quality, safety and efficiency.

[0003] Patent CN109699848A discloses a biological preparation for treating tilapia streptococcal disease, which is prepared by sterilization of a fermentation tank, preparation of a culture medium, sterilization of a culture medium, inoculation of bacteria, fermentation of bacteria, concentration, drying, crushing and screening. The preparation method of the biological preparation is complex and has a high cost. Summary of the invention

[0004] The technical problem solved by the invention is to provide an application of alpha-mangostin and its derivatives in the preparation of feed additives for preventing and treating dolphin streptococcal disease in fish.

[0005] α-Mangostin and its derivatives have good preventive and therapeutic effects on fish dolphin streptococcal disease and are safe and non-toxic to fish. They can be used as feed additives to prevent and control dolphin streptococcal disease in fish.

[0006] In one embodiment of the present invention, the α-mangostin and its derivatives are α-mangostin, β-mangostin or γ-mangostin.

[0007] In one embodiment of the present invention, the feed additive is a powder.

[0008] In one embodiment of the present invention, the fish is tilapia or golden pomfret.

[0009] The invention also provides a feed for preventing and treating fish dolphin streptococcus disease.

[0010] The feed for preventing and treating fish dolphin streptococcus disease comprises fish feed and alpha-mangostin.

[0011] In one embodiment of the present invention, the ratio of fish feed to α-mangostin is: 1kg: 100-1000mg.

[0012] In one embodiment of the present invention, the fish is tilapia or golden pomfret.

[0013] Compared with the prior art, the present invention has the following beneficial effects:

[0014] 1. The present invention is the first to use the natural compound α-mangostin as a feed additive to prevent and treat dolphin streptococcal disease in fish, especially dolphin streptococcal disease in tilapia. Within an effective dose, the relative survival rate of diseased tilapia can be increased to 32.14% to 67.86%.

[0015] 2. α-Mangostin is a natural compound with good biocompatibility, low side effects, and an industrial preparation process. It has great potential to be developed into a new feed additive for the prevention and treatment of Streptococcus dolphinus in fish, and has broad application prospects.

[0016] 3. Through in vitro antibacterial experiments, acute toxicity experiments on tilapia and artificial infection animal disease model experiments, it is proved that α-mangostin has a good preventive and therapeutic effect on fish dolphin streptococcal disease. When the concentration of α-mangostin is 10μg / mL, the antibacterial rate of dolphin streptococcus is as high as 100%. The antibacterial zone is 11.32mm, which has an antibacterial effect. The therapeutic effect of feeding tilapia infected with dolphin streptococcus reached 32.14% to 67.86%; α-mangostin is easily metabolized and eliminated in the host body, and easily degraded and eliminated in the environment. It can effectively avoid drug residues and environmental pollution and problems caused by the abuse of chemical drugs, which is conducive to promoting the sustainable and healthy development of aquaculture. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a cumulative mortality curve of tilapia infected with different concentrations of Streptococcus iniae in Example 3.

[0018] Figure 2 This is a graph showing the relative survival rates of tilapia infected with S. iniae at different doses of α-mangostin in Example 3. In the graph, “*” indicates that there is a significant difference in the survival rate between the fish in different experimental groups and the control group, *p<0.05; “**” indicates that there is a very significant difference, **p<0.01. DETAILED DESCRIPTION

[0019] α-Mangostin is a yellow powdery compound of the xanthone class isolated from the mangosteen shell of the plant Garcinia L. of the family Garciniaceae. It is insoluble in water but easily soluble in organic solvents such as n-hexane, chloroform, and ethyl acetate. Its molecular formula is C 24 H 26 O6, whose structural formula is:

[0020]

[0021] It is reported that α-mangostin has the following functions: 1. Anti-cancer activity, inhibiting the proliferation of tumor cells by regulating apoptosis proteins; 2. Anti-oxidation, blocking the oxidation of low-density lipoprotein (LDL) produced by the stimulation of peroxide or copper free radicals, and scavenging reactive oxygen species (ROS) free radicals; 3. Anti-inflammatory, exerting anti-inflammatory effects by inhibiting the release of inflammatory mediators in human cells; 4. Antiviral, interfering with viral replication by preventing the action of proteases; 5. Neuroinflammatory and neuroprotective properties. Neuroinflammation can cause diseases such as Alzheimer's and Parkinson's diseases, and α-mangostin can reduce the occurrence of neuroinflammation and reduce the risk of disease.

[0022] The present invention finds that alpha-mangostin has a good preventive and therapeutic effect on fish streptococcus dolphin disease, is safe and non-toxic to fish, and can be used as a feed additive for the prevention and treatment of fish streptococcus dolphin disease.

[0023] In one embodiment of the present invention, the α-mangostin and its derivatives are α-mangostin, β-mangostin or γ-mangostin.

[0024] In one embodiment of the present invention, the fish is tilapia or golden pomfret.

[0025] The feed additive can be directly α-mangostin and its derivatives, or can be feed additives in different dosage forms prepared by combining α-mangostin and its derivatives with carriers and excipients acceptable to feed additives. In one embodiment of the present invention, the feed additive is a powder.

[0026] The invention also provides a feed for preventing and treating fish dolphin streptococcus disease.

[0027] The feed for preventing and treating fish dolphin streptococcus disease comprises fish feed and alpha-mangostin.

[0028] In one embodiment of the present invention, the ratio of fish feed to α-mangostin is: 1kg: 100-1000mg.

[0029] The fish feed is commonly used in the art and will not be described in detail here.

[0030] In one embodiment of the present invention, the fish is tilapia or golden pomfret.

[0031] The specific implementation of the present invention is further described below in conjunction with the examples, and the present invention is not limited to the scope of the examples. The host used in the examples is tilapia, purchased from Guangzhou Yufeng Aquatic Seedling Base. The starting bacteria of the pathogen is Streptococcus iniae, which was isolated and purified from the body of silver pomfret in this laboratory and identified as Streptococcus iniae by morphological and 16S rDNA molecular biological methods.

[0032] Example 1 In vitro antibacterial experiment of α-mangostin on Streptococcus iniae

[0033] 1. Preparation of Streptococcus iniae suspension

[0034] Take out the Streptococcus iniae strain from -80℃, thaw at room temperature, streak on brain heart infusion (BHI) solid medium, and culture at 30℃ for 24h. Pick a single colony, inoculate it into BHI liquid medium, and culture it in a shaker at 30℃ and 180r / min for 24h. Centrifuge at 5000r / min for 5min, collect the bacteria, wash them three times with phosphate buffered saline (PBS) at pH=7, and adjust the concentration of the bacterial suspension with PBS buffer to reach OD 620nm =1.0(2.5×10 9 CFU / mL) and kept at 4℃ for later use.

[0035] 2. Determination of the inhibition rate of α-mangostin on S. iniae by microplate method

[0036] Take a 96-well plate and fill the wells around it with sterile deionized water. Only 8 μL of pure dimethyl sulfoxide (DMSO) solvent was added to the 6 wells B2, C2, D2, E2, F2 and G2 as a negative control. The sample group set up 6 parallel wells, and 8 μL of α-mangostin solution was added to these 6 wells to make the final concentration reach 10 μg / mL. 200 μL of bacterial suspension was added to the control wells and sample wells and mixed evenly. The absorbance of each well was measured at a wavelength of 620 nm using an enzyme reader, and the samples were cultured at 30°C for 18 h. The measured results showed that the absorbance values ​​of the sample group were basically consistent before and after culture. The results were calculated using the formula. The absorbance of the sample group was 0.169±0.0097 and 0.161±0.004 before and after culture, and the absorbance of the control group was 0.080±0.0023 and 0.437±0.019 before and after culture. Finally, the formula was used to calculate that the inhibition rate of the 10 μg / mL α-mangostin sample solution on Streptococcus indiae was as high as 100%.

[0037] I α =((A 620nm 0-A 620nm 1)-(A 620nmα-A 620nmα1 ))×100% / A0

[0038] Where: A 620nm 0 is the average absorbance value at 620 nm of the negative control group after culture;

[0039] A 620nm 1 is the average absorbance value at 620 nm of the negative control group before culture;

[0040] A 620nmα is the average absorbance value at 620nm of the sample group;

[0041] A 620nmα1 is the average absorbance value at 620 nm of the α-mangostin group before culture;

[0042] I a is the inhibition rate of sterile natural compounds against S. iniae;

[0043] A0 is (A 620nm 0-A 620nm 1).

[0044] 3. Agar diffusion method to determine the in vitro antibacterial activity of α-mangostin

[0045] (1) Dilute with PBS buffer to OD 620nm =1 bacterial suspension.

[0046] (2) Preparation of double-layer agar: The lower medium is BHI solid medium, and the upper medium is BHI semi-solid medium containing 50% agar and added with bacterial suspension. Place the sterilized BHI semi-solid medium in a 50°C water bath and allow it to cool slowly. When the semi-solid medium is not hot to the touch, add 2% bacterial Streptococcus dolphinus suspension and pour it into the solid medium to allow it to cool slowly until solidified.

[0047] (3) Use a 5 mm diameter borer to drill three holes evenly distributed on the double-layer culture medium.

[0048] (4) Add 50 μL of 100 μg / mL α-mangostin solution to the culture dish and let it stand for 30 min, then incubate at 30°C for 18 h, and use a vernier caliper to measure the diameter of the inhibition zone. The result is: the diameter of the inhibition zone of α-mangostin is 11.32 mm.

[0049] 4. Determination of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC)

[0050] Take a 96-well plate, fill the wells around it with sterile deionized water, add the Streptococcus dolphin suspension and BHI medium to the wells of the 96-well plate, add α-mangostin solution with concentrations of 100, 50, 25, 12.5, 6.25, 3.125, 1.56, and 0.78 μg / mL to each experimental well, respectively, and culture in a constant temperature incubator at 30°C for 12 hours, then take out the 96-well plate and place it in an ELISA reader to detect the OD of each well. 620 nm value.

[0051] (1) Preparation of α-mangostin solution: OD 620 nm = 1.0 bacterial suspension diluted to OD 620 nm =0.1; use pure DMSO solvent with a 0.22μm microporous filter to dissolve α-mangostin and prepare a solution with a concentration of 100mg / mL. Take 8 test tubes, add an appropriate amount of α-mangostin solution to the first test tube, dilute it to 100μg / mL with the adjusted bacterial suspension, and use the bacterial suspension to perform a two-fold gradient dilution of the drug concentration to dilute it into α-mangostin solutions with concentrations of 100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78μg / mL, and use an equal amount of pure DMSO as a negative control;

[0052] (2) Transfer the sample solution from low to high into a 96-well plate and add it to each well. Add three wells in parallel for each concentration, with 200 μL in each well.

[0053] (3) Place them in a constant temperature incubator at 30°C and incubate for 12 hours. Measure the absorbance of each well with a microplate reader. From high to low concentrations, the first concentration whose absorbance is lower than 10% of the control group is called the MIC.

[0054] (4) Based on the MIC, 20 μL of sample solution was taken from each well and evenly spread on BHI solid culture medium. After incubation at 30°C for 24 h, the concentration on the solid culture medium at which no bacteria were found was taken as the MBC.

[0055] The final results showed that the MIC and MBC of α-mangostin against Streptococcus iniae were 0.78μg / mL and 1.56μg / mL, respectively.

[0056] Example 2 Acute toxicity test of α-mangostin on tilapia

[0057] 1. Preparation of the drug solution

[0058] Weigh an appropriate amount of α-mangostin into a 1.5 mL centrifuge tube, add 1 mL of pure DMSO to dissolve it, and dilute it with PBS buffer to a final concentration of 50 mg / mL, 25 mg / mL, and 12.5 mg / mL for later use.

[0059] 2. Feeding tilapia with α-mangostin solution

[0060] 128 healthy tilapia with a body length of 8±2cm were selected and randomly assigned to 8 aquariums (0.8m×0.50m×0.55m), with 16 fish in each aquarium. The 8 aquariums were randomly assigned to 3 experimental groups and a control group, with 2 aquariums in each group. The water temperature of the aquarium was maintained at 30±2℃, and the dissolved oxygen (DO) in the water was greater than 6.5mg / L. The fish were kept for 7 days, and half of the water was changed every 2 days. The fish were fasted for 12h before gavage, and were gavaged twice at a dose of 0.2mL / 20g with an interval of 4h, so that the gavage dose of α-mangostin for each fish reached 250mg / kg, 500mg / kg, and 1000mg / kg. The control group was gavaged with the same dose of PBS solution without drugs, and continued to be raised under the original feeding conditions for 14d. The behavior of the experimental fish was noted and their health status was recorded.

[0061] After 14 days of observation, the fish in both the experimental and control groups showed no fatal symptoms, their behavior remained good, and they were able to take in feed on time. A careful examination of their appearance showed no changes. In addition, when all the tilapia were dissected, no water or sticky substances were found in the abdomen, and no swelling of the organs was found.

[0062] Example 3 The therapeutic effect of α-mangostin on tilapia streptococcal disease

[0063] 1. Preparation of injection bacterial suspension: Reference Example 1, Streptococcus india suspension

[0064] 2. Establishment of Tilapia Disease Model Infected with Streptococcus iniae

[0065] 240 healthy tilapia with a body length of 8±2cm were selected and randomly assigned to 12 aquariums (0.8m×0.50m×0.55m), with 20 fish in each aquarium. The 8 aquariums were divided into 5 experimental groups and 1 control group (see Table 1), with 2 aquariums in each group. The water temperature of the aquarium was maintained at 30±2℃ and DO was greater than 6.5mg / L. Half of the water was changed every 2 days. Tilapias were fasted for 12h before infection. The 5 experimental groups were injected with iniae Streptococcus suspension to cause infection. The negative control group was injected with PBS buffer. The injection dose is shown in Table 1. The injected tilapia were raised under the original feeding conditions for 14d. Pay attention to the behavior of the experimental fish and record their health status. The dead fish in the experiment were also recorded.

[0066] Table 1 Establishment of the disease model of Tilapia infected with Streptococcus indica

[0067]

[0068]

[0069] Note: OD of S. iniae 620nm =1, that is, 2.5×10 9 CFU / mL; injection volume 0.1mL / 20g.

[0070] After intraperitoneal injection of different concentrations of Streptococcus dolphins, the movement of tilapia showed obvious abnormalities. The swimming became slow, and some even stayed in place and lost balance. The cornea became blurred, the body color became dark, and bleeding and ulcers appeared in some parts of the body. The pathogen was re-isolated and identified from the dying tilapia, and the infected pathogen was identified as Streptococcus dolphins.

[0071] The cumulative mortality curves of tilapia in each group after infection are as follows Figure 1 The relationship between mortality and bacterial concentration is shown in Figure 2. The equation for fitting the mortality rate and bacterial concentration is y = 0.205 × Lg (x) - 1.1266 (R 2 =0.9617). The LD of tilapia is obtained from the equation 80 1.25×10 10 CFU / kg. Pathogen identification results The strains isolated and purified from tilapia were all Streptococcus iniae by 16S-rDNA detection. From the cumulative death curves of tilapia infected with different concentrations of Streptococcus iniae, it can be concluded that the higher the challenge dose, the more tilapia deaths.

[0072] 3. α-Mangostin mixed feed fed to tilapia infected with Streptococcus iniae

[0073] 160 healthy tilapia with a body length of 8±2cm were selected and placed in 8 aquariums (0.80m×0.50m×0.55m), with 16 fish in each aquarium. The 8 aquariums were randomly divided into 3 experimental groups, 1 positive control group and 1 negative control group (see Table 2), with 2 aquariums in each group. The aquarium temperature was maintained at 30±2℃ and the DO was greater than 6.5mg / L. The fish were fed with a 7-day basic feed, with a stocking density of 20 fish / 220L (0.8m×0.5m×0.55m), and half of the water was replaced every 2 days. LD of intraperitoneal injection of Streptococcus iniae 80 (1.25×10 10 CFU / kg) dose, fasting for 12 h before injection, feeding feed 2 h after injection (injection dose and feed drug concentration are shown in Table 2), and the injected tilapia were raised under the original feeding conditions for 14 d, paying attention to the behavior of the experimental fish, recording their health status, and also recording the dead fish in the experiment.

[0074] The mice were fed feeds containing 0mg / kg, 100mg / kg, 200mg / kg, and 400mg / kg of α-mangostin. The results were observed for 14 days. Figure 2 As shown, the relative protection rates (RPS) in the α-mangostin experimental group were 32.14%, 53.57% and 67.86%, respectively.

[0075] Table 2 Study on the therapeutic effect of α-mangostin on tilapia streptococcal disease

[0076] Group Challenge dose α-mangostin concentration Uninfected group PBS 0g / kg Infection group <![CDATA[1.25×10 10 CFU / kg]]> 0g / kg Low concentration dose <![CDATA[1.25×10 10 CFU / kg]]> 100mg / kg Medium concentration dose <![CDATA[1.25×10 10 CFU / kg]]> 200mg / kg High concentration dose <![CDATA[1.25×10 10 CFU / kg]]> 400mg / kg

[0077] Note: OD of S. iniae 620nm =1, that is, 2.5×10 9 CFU / mL; injection volume 0.1mL / 20g.

[0078] Re-isolation and purification of pathogens: Check the external symptoms of dying tilapia and fish them out. Dip the lesion site of the diseased fish with an inoculation loop on a clean bench, streak it on a BHI solid agar plate, and incubate it upside down in a 30°C constant temperature incubator for 24 hours. Observe the colony morphology of the isolated strain, pick the dominant colonies with the same morphology and size, streak them on a newly prepared BHI solid agar plate, and obtain purified single colonies.

[0079] 16S-rDNA gene amplification and identification: Lysozyme was used to break the cell wall and the template DNA was initially obtained. A 25 μL reaction system was prepared as shown in Table 3. 5 μL of PCR product was taken on a 1% agarose gel and electrophoresed at 180V for 20 min. An obvious band appeared near 1500 bp. The remaining product was sent to Guangzhou BGI Genomics Technology Co., Ltd. for sequence sequencing.

[0080] Table 3 25μL PCR reaction system

[0081] Reagents Volume (μL) Mix 12.5 <![CDATA[ddH2O]]> 9.5 F 1 R 1 Template DNA 1

[0082] (3) Sequence alignment: The species information of the bacterial species can be obtained through preliminary analysis of the sequencing data provided by the company and comparison with NCBI.

[0083] (4) Conclusion: According to the comparison results, all the tilapia tested were infected with Streptococcus dolphinus.

Claims

1. Application of α-mangostin and its derivatives in the preparation of feed additives for preventing and treating dolphin streptococcal disease in fish; the α-mangostin and its derivatives are α-mangostin, β-mangostin or γ-mangostin; the fish is tilapia or golden pomfret.

2. The use of α-mangostin and its derivatives according to claim 1 in the preparation of a feed additive for preventing and treating dolphin streptococcal disease in fish, characterized in that the feed additive is a powder.

Citation Information

Patent Citations

  • Biological preparation for treating streptococcus iniae of Tilapia

    CN109699848A

  • Mangosteen fermentation extract, preparation method and application

    CN112535237A

  • Application of mangosteen extract alpha-mangostin in preparation of medicine for preventing and treating livestock and poultry clostridium perfringens infection

    CN114452281A

  • Mangosteen extract and application of active components thereof

    CN115944659A

  • Preparation method and application of mangosteen extract

    CN116139191A